Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies

Fig. 4

Heat map of enthesitis resolution by treatment group through week 104. The asterisk indicate discontinuation due to following reasons: adverse events, death, lack of efficacy, lost to follow-up, non-compliance with study treatment, physician decision, pregnancy, patient/guardian decision, and withdrawal of informed consent. Placebo patients switched therapies at week 16 or 24. All patients with enthesitis at baseline were followed until the end of study or discontinuation. BL, baseline, EC, enthesitis count; W, week

Back to article page